Related Experiment Video

Updated: Jun 21, 2026

Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
10:50

Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo

Published on: March 26, 2019

[Minimal hepatic encephalopathy]

M Jover1, E Hoyas, L Grande

  • 1UGC Enfermedades Digestivas & Ciberehd, Hospital Universitario de Valme, Sevilla.

Revista De Gastroenterologia De Mexico
|August 12, 2009
PubMed

Insights

Minimal hepatic encephalopathy (MHE) affects one-third of cirrhosis patients, impacting quality of life and increasing risks. Early diagnosis through tests like PHES is crucial for managing this early stage of hepatic encephalopathy.

Area of Science:

  • Hepatology
  • Neurology
  • Gastroenterology

Context:

  • Minimal hepatic encephalopathy (MHE) is a prevalent complication in cirrhotic patients, affecting up to one-third.
  • MHE is characterized by neurophysiological alterations impacting daily activities and increasing the risk of overt hepatic encephalopathy.
  • The condition significantly diminishes patients' quality of life.

Purpose:

  • To define Minimal Hepatic Encephalopathy (MHE) and its clinical significance.
  • To review diagnostic methods for MHE, including psychometric and neurophysiological tests.
  • To highlight the prognostic value of the oral glutamine challenge (OGC) test.

Summary:

  • MHE presents with neurophysiological changes in a significant portion of cirrhosis patients.
  • Diagnosis utilizes tools such as the Psychometric Hepatic Encephalopathy Score (PHES), electroencephalogram, and critical flicker frequency.
  • Altered oral glutamine challenge (OGC) results indicate increased intestinal ammonia production and predict short-term survival.

Impact:

  • MHE represents the initial stage of hepatic encephalopathy (HE) syndrome.
  • Early identification and management of MHE are essential for improving patient outcomes and quality of life.
  • Further research into novel therapeutic strategies for MHE is warranted.

More Related Videos

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy10:30

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy

Published on: May 16, 2015

Related Concept Videos

Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Cerebral Edema ll: Pathophysiology01:22

Cerebral Edema ll: Pathophysiology

Vasogenic edema is a major form of cerebral edema characterized by abnormal accumulation of fluid in the brain’s extracellular space due to disruption of the blood–brain barrier (BBB). The BBB is a specialized structure composed of endothelial cells connected by tight junctions, supported by astrocytic endfeet and a basement membrane. Under normal conditions, it tightly regulates the movement of ions, proteins, and solutes between the bloodstream and brain parenchyma. When this barrier loses...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...